HC Wainwright Reiterates “Buy” Rating for Stealth BioTherapeutics (NASDAQ:MITO)

HC Wainwright reaffirmed their buy rating on shares of Stealth BioTherapeutics (NASDAQ:MITO) in a research report released on Friday morning, AnalystRatings.com reports. HC Wainwright currently has a $30.00 price target on the stock.

Separately, Zacks Investment Research downgraded HEXO from a hold rating to a sell rating in a research report on Wednesday, May 15th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Stealth BioTherapeutics has a consensus rating of Buy and an average price target of $24.83.

Shares of MITO stock opened at $11.12 on Friday. The stock has a 50 day moving average price of $12.46. Stealth BioTherapeutics has a 12 month low of $11.05 and a 12 month high of $20.99. The company has a market cap of $310.72 million and a P/E ratio of -7.89.

Stealth BioTherapeutics (NASDAQ:MITO) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.14. Sell-side analysts anticipate that Stealth BioTherapeutics will post -0.18 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC bought a new position in Stealth BioTherapeutics Corp (NASDAQ:MITO) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned approximately 0.18% of Stealth BioTherapeutics at the end of the most recent quarter. Institutional investors own 1.09% of the company’s stock.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Further Reading: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.